Manifold Bio

Manifold Bio Manifold bio has built the first high throughput in vivo discovery engine—combining massively multiplexed in vivo screening and ai powered design to create tissue targeted biologics while building the virtual organism. Today’s essay is about manifold bio, a promising boston based startup that spun out of the church lab at harvard. in many ways, their story is a continuation of the key themes of this newsletter.

Manifold Bio Roche may have been exploring ways to shuttle drugs to the brain for well over a decade, but that’s not stopping the pharma from handing $55 million to manifold bio for a fresh route through. Organism scale intelligence, designed in vivo | manifold bio is a platform therapeutics company building the first ai guided direct to vivo discovery platform. Explore manifold bio's in depth company profile, including funding details, key investors, leadership, competitors, and acquisitions. Manifold bio is a biotechnology company that features a platform that enables multiplexed quantitation of protein therapeutic designs, generating unprecedented data throughout the drug development process to unlock measurement driven design.

Manifold Bio High Throughput In Vivo Drug Design Explore manifold bio's in depth company profile, including funding details, key investors, leadership, competitors, and acquisitions. Manifold bio is a biotechnology company that features a platform that enables multiplexed quantitation of protein therapeutic designs, generating unprecedented data throughout the drug development process to unlock measurement driven design. Manifold used its proprietary platform to test 1 million binder designs against 127 targets in a single multiplexed experiment, measuring over 100 million protein protein interactions. Boston based biotech manifold bio has entered into a strategic collaboration with pharma giant roche to develop a portfolio of next generation “brain shuttles” for the treatment of neurodegenerative diseases. Manifold bio thinks the way to finally crack tissue specific delivery of biologics is to conduct discovery work in vivo. six years in, the boston based bio. Manifold bio has developed a proprietary high throughput in vivo drug design platform using protein barcoding ("mcodes") that enables simultaneous testing of hundreds of therapeutic candidates within living systems.